| Proteome-wide profiling of clinical PARP inhibitors reveals compound-specific secondary targets CE Knezevic, G Wright, LLR Rix, W Kim, BM Kuenzi, Y Luo, JM Watters, ... Cell chemical biology 23 (12), 1490-1503, 2016 | 111 | 2016 |
| Structure and mechanism of a canonical poly (ADP-ribose) glycohydrolase MS Dunstan, E Barkauskaite, P Lafite, CE Knezevic, A Brassington, ... Nature communications 3 (1), 878, 2012 | 101 | 2012 |
| Chemoproteomics reveals novel protein and lipid kinase targets of clinical CDK4/6 inhibitors in lung cancer NJ Sumi, BM Kuenzi, CE Knezevic, LL Remsing Rix, U Rix ACS chemical biology 10 (12), 2680-2686, 2015 | 90 | 2015 |
| Cancer chemotherapy: The case for therapeutic drug monitoring CE Knezevic, W Clarke Therapeutic drug monitoring 42 (1), 6-19, 2020 | 84 | 2020 |
| Synthesis of (±)-actinophyllic acid and analogs: Applications of cascade reactions and diverted total synthesis BA Granger, IT Jewett, JD Butler, B Hua, CE Knezevic, EI Parkinson, ... Journal of the American Chemical Society 135 (35), 12984-12986, 2013 | 77 | 2013 |
| Selective small molecule inhibition of poly (ADP-ribose) glycohydrolase (PARG) KE Finch, CE Knezevic, AC Nottbohm, KC Partlow, PJ Hergenrother ACS chemical biology 7 (3), 563-570, 2012 | 69 | 2012 |
| Advancements in the gold standard: Measuring steroid sex hormones by mass spectrometry SE Conklin, CE Knezevic Clinical Biochemistry 82, 21-32, 2020 | 58 | 2020 |
| The non-canonical target PARP16 contributes to polypharmacology of the PARP inhibitor talazoparib and its synergy with WEE1 inhibitors V Palve, CE Knezevic, DS Bejan, Y Luo, X Li, S Novakova, EA Welsh, ... Cell chemical biology 29 (2), 202-214. e7, 2022 | 30 | 2022 |
| Establishing hemolysis and lipemia acceptance thresholds for clinical chemistry tests CE Knezevic, MA Ness, PHT Tsang, BJ Tenney, MA Marzinke Clinica Chimica Acta 510, 459-465, 2020 | 20 | 2020 |
| Brønsted Acid Catalyzed C3-Alkylation of 2-Indolylmethanols with Azlactones via an Umpolung Strategy Y Shen, ZQ Zhu, JX Liu, L Yu, BX Du, GJ Mei, F Shi Synthesis 49 (17), 4025-4034, 2017 | 19 | 2017 |
| A copper (II)-catalyzed, sequential Michael–aldol reaction for the preparation of 1, 2-dihydroquinolines AM Wagner, CE Knezevic, JL Wall, VL Sun, JA Buss, LAT Allen, ... Tetrahedron Letters 53 (7), 833-836, 2012 | 19 | 2012 |
| Clinical use and monitoring of antiepileptic drugs CE Knezevic, MA Marzinke Journal of Applied Laboratory Medicine 3 (1), 115-127, 2018 | 17 | 2018 |
| Electron‐Withdrawing, Biphenyl‐2, 2′‐diol‐Based Compounds for Asymmetric Catalysis EG Gutierrez, EJ Moorhead, EH Smith, V Lin, LKG Ackerman, ... European Journal of Organic Chemistry 2010 (16), 3027-3031, 2010 | 17 | 2010 |
| Evaluation of serum and rapid serum separator collection tubes for therapeutic drug assays KY Garza, J Carter, A Mercer, P Jarrar, J Martin, S Daughtry, A Mahomes, ... Clinical Biochemistry 115, 81-85, 2023 | 7 | 2023 |
| Cannabis positivity rates in 17 emergency departments across the United States with varying degrees of marijuana legalization NV Tolan, MD Krasowski, PC Mathias, JR Wiencek, N Babic, PR Chai, ... Clinical Toxicology 61 (4), 248-259, 2023 | 6 | 2023 |
| Elevated creatinine in a patient on IVIG-therapy CE Knezevic, MA Ness, LE Kratz, MA Marzinke Clinica Chimica Acta 486, 94-97, 2018 | 6 | 2018 |
| Rising to the challenge: Shortages in laboratory medicine CE Knezevic, B Das, JM El-Khoury, PJ Jannetto, F Lacbawan, WE Winter Clinical chemistry 68 (12), 1486-1492, 2022 | 5 | 2022 |
| Urine drug screens: Caveats for interpreting results S Thomas, C Knezevic MJH Life Sciences, 2019 | 2 | 2019 |
| Development of poly (ADP-ribose) glycohydrolase inhibitors and tetracyclic indoles as anticancer compounds C Knezevic University of Illinois at Urbana-Champaign, 2014 | 2 | 2014 |
| Chemoproteomics Reveals Novel Protein and Lipid Kinase Targets of Clinical CDK4/6 Inhibitors in Lung Cancer. ACS Chem Biol. 2015; 10: 2680–86 NJ Sumi, BM Kuenzi, CE Knezevic, LL Remsing Rix, U Rix | 2 | |
